Crizanlizumab

Drug Profile

Crizanlizumab

Alternative Names: SEG 101; Sel G1

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator Selexys Pharmaceuticals
  • Developer Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sickle cell anaemia

Most Recent Events

  • 03 Dec 2016 Efficacy data from the SUSTAIN phase II trial in Sickle cell anaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology
  • 03 Dec 2016 Final efficacy data from the phase II SUSTAIN trial in Sickle cell anaemia released by Novartis
  • 21 Nov 2016 Selexys Pharmaceuticals has been acquired and merged into Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top